Cabazitaxel Plus Carboplatin for the Treatment of Men With Metastatic Castration-Resistant Prostate Cancer

[snoraste]

In case you didn't see this. Early phase I/II results encourage combination therapy. Of course more work needs to get done to see who would benefit most.

"TAKE-HOME MESSAGE

This phase I/II trial evaluated the combination of cabazitaxel and carboplatin for patients with metastatic castration-resistant prostate cancer. The combination of cabazitaxel and carboplatin was associated with longer median progression-free survival over cabazitaxel alone (7.3 months vs 4.5 months).

The combination was associated with increased toxicity, but there were no dose-limiting toxicities, and the treatment was generally safe and well-tolerated."

practiceupdate.com/C/89458/...

[DarkEnergy]

This link does not require registration:

thelancet.com/journals/lano...